Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

Published:2018-01-29 Issue:6 Volume:47 Page:753-762
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Christensen B.¹²³^ORCID,Micic D.⁴,Gibson P. R.¹,Yarur A.⁵,Bellaguarda E.⁴,Corsello P.⁶,Gaetano J. N.³,Kinnucan J.⁶,Rao V. L.³,Reddy S.⁴,Singh S.⁵,Pekow J.³,Rubin D. T.³

Affiliation:

1. Alfred Hospital and Monash University; Melbourne Australia

2. Royal Melbourne Hospital; Melbourne Australia

3. University of Chicago Medicine Inflammatory Bowel Disease Center; Chicago IL USA

4. Northwestern University Feinberg School of Medicine; Chicago IL USA

5. Division of Gastroenterology and Hepatology; Medical College of Wisconsin; Milwaukee WI USA

6. University of Michigan Health System; Ann Arbor MI USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14525/fullpdf

Reference40 articles.

1. Primary sclerosing cholangitis;Hirschfield;Lancet,2013

2. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease;Boonstra;Inflamm Bowel Dis,2012

3. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management;Eaton;Gastroenterology,2013

4. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease;Porayko;Gastroenterology,1990

5. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited;Paumgartner;Hepatology,2002

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta‐analysis;Journal of Gastroenterology and Hepatology;2024-05-13

2. Efficacy of Biologics in the Treatment of Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis;Cureus;2024-03-14

3. Primary sclerosing cholangitis and inflammatory bowel disease: a complicated yet unique relationship;Minerva Gastroenterology;2024-02

4. Integrins in biliary injury and fibrosis;Current Opinion in Gastroenterology;2024-01-02

5. Gut Microbiota in Primary Sclerosing Cholangitis: From Prognostic Role to Therapeutic Implications;Digestive Diseases;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3